THE ECONOMICS OF CARDIAC-FAILURE

Quality assurance and inclusion of prospective evaluation of costs of treatment in phase 3 and 4 pharmaceutical trials are becoming increasi ngly important. Not only high technology applications have to be inves tigated, but also relatively cheap but very common strategies for diag nostic work up and therapy. This may yield major savings. We are at th e beginning of an era in which waste of resources may be reduced by sc ientific analysis with improvement in patient care and teaching achiev ed as a result.